Cellebrite
CLBT
197 hedge funds and large institutions have $2.4B invested in Cellebrite in 2025 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 79 increasing their positions, 51 reducing their positions, and 55 closing their positions.
77% more call options, than puts
Call options by funds: $9.19M | Put options by funds: $5.2M
55% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 51
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
27% more capital invested
Capital invested by funds: $1.89B → $2.4B (+$511M)
4.78% more ownership
Funds ownership: 49.3% → 54.08% (+4.8%)
6% less funds holding
Funds holding: 209 → 197 (-12)
20% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$55.4M |
| 2 |
CCPM
Cooper Creek Partners Management
New York
|
+$47.5M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$37.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$32.3M |
| 5 |
PP
Pertento Partners
London,
United Kingdom
|
+$26.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
Axon Enterprise
Scottsdale,
Arizona
|
-$83.6M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$29.2M |
| 3 |
Morgan Stanley
New York
|
-$27.8M |
| 4 |
Two Sigma Advisers
New York
|
-$21.6M |
| 5 |
Millennium Management
New York
|
-$19.8M |
CLBT Hedge Fund Activity: Q3 2025 in Review
197 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Cellebrite (CLBT) for Q3 2025, worth a combined $2.4B — up 27% from $1.89B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of CLBT and 44 opened new positions — a net loss of 11 holders — while 51 trimmed existing stakes and 79 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $55.4M. The largest seller was Axon Enterprise, cutting an estimated $83.6M.
- 197 institutional investors held Cellebrite (CLBT) as of Q3 2025, down from 209 in Q2 2025.
- Funds reported $2.4B of Cellebrite stock for Q3 2025, up 27% quarter-over-quarter.
- 44 funds opened new Cellebrite positions in Q3 2025 and 55 closed out, a net change of -11 holders.
- The largest Cellebrite buyer in Q3 2025 was T. Rowe Price Investment Management, an estimated $55.4M added.
- The largest Cellebrite seller in Q3 2025 was Axon Enterprise, an estimated $83.6M sold.
Based on aggregated 13F filings for Q3 2025.